Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Elucigene DPYD

UK-based Yourgene has launched the Elucigene DPYD assay, a CE-marked chemotoxicity diagnostic test that uses genotyping to identify cancer patients with dihydropyrimidine dehydrogenase (DPD) deficiency. The deficiency causes several and sometimes lethal side effects in patients treated with 5-fluorouracil (5-FU), which is metabolized by the DPD enzyme, encoded by the DPYD gene. Elucigene DPYD, which tests for six common genetic variations, conforms with Clinical Pharmacogenetics Consortium guidelines, which recommend testing for four clinically relevant mutations.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.